Effect of Local Versus General Anesthesia in Breast-Conserving Surgery on Cancer Recurrence and Cost

Chongshan Gu, MD1, Lize Wang, MD1, Yingjian He, MD1, Tao Ouyang, MD1, Jinfeng Li, MD1, Tianfeng Wang, MD1, Tie Fan, MD1, Mi Li, MD2, and Zhaoqing Fan, MD1

Abstract
Background: The association between the type of anesthesia used and the recurrence of cancer remains controversial. This study aimed to compare the effects of local vs general anesthesia on recurrence-free survival and cost after breast-conserving surgery.

Materials and Methods: We reviewed the data of 2778 patients who underwent breast-conserving surgery followed by radiation at our center between 1999 and 2014. We analyzed the data of 994 patients with hormone receptor-positive and Her2-negative tumors who underwent breast-conserving surgery without axillary lymph node dissection under local or general anesthesia. Patients were grouped according to whether local or general anesthesia was used for the surgery.

Results: Of the 994 patients enrolled in this study, 367 received local anesthesia and 627 patients received general anesthesia. The median follow-up duration for all patients was 93 months. The Kaplan–Meier survival curves did not reveal significant differences between the recurrence-free survival of the two groups, with 5-year recurrence-free survival rates of 96.3% (95% CI, 94.3–98.3%) in the local anesthesia group and 97.3% (95% CI, 95.9–98.7%) in the general anesthesia group. The total cost of hospitalization in the local anesthesia group was significantly lower than that in the general anesthesia group (P <.001). The difference in the cost between the two groups remained significant, irrespective of the type of hospitalization, after excluding 165 patients receiving chemotherapy during their hospitalization.

Conclusions: Our analysis indicated no association between the type of anesthesia used during breast-conserving surgery and the long-term prognosis of breast cancer. However, breast-conserving surgery under local anesthesia may be a less expensive option than that under general anesthesia.

Keywords
breast-conserving surgery, local anesthesia, general anesthesia, survival, cost

Introduction
Breast cancer is the most common cancer affecting women worldwide.1 Breast-conserving surgery, in conjunction with radiation therapy, has become a routine treatment, which yields survival rates equivalent to those of mastectomy in early-stage breast cancer.2-6 There has been some debate regarding the influence of anesthetic agents on the recurrence of breast cancer.7 Previous clinical studies have compared the regional and general anesthetic approaches, and several studies have shown that local anesthetics significantly inhibit cancer cell survival in vitro.8-9 However, the...
The initial skin infiltration was performed and the local anesthetic solution was infiltrated around the marked lump/lesion. The administration of local anesthesia was performed slowly, on either side, above, and below the lump. If necessary, another 50 mL of the solution was administered.

Surgical Procedures

Sentinel lymph node biopsy with a 99mTc-labeled rituximab tracer was performed before breast-conserving surgery. The tumors were localized preoperatively using ultrasonography or marked with skin tattoos prior to the administration of neoadjuvant treatment. During breast-conserving surgery, surgeons attempted to remove .5–1 cm of normal tissue with the primary tumor. Glandular reshaping was utilized to close the defect and improve the long-term cosmetic outcomes. If a positive margin was identified on the intraoperative frozen section, additional tissue was excised during the same surgery according to the patient’s surgical cavity to obtain a negative margin. The final margin status was determined by examining the permanent paraffin-embedded sections.

Follow-up

The duration of follow-up was calculated from the date of surgery. Patients were advised to undergo examination every 6 months after surgery for the first 5 years of follow-up, and annually thereafter. Ultrasonography was performed at each follow-up examination and mammography was performed on an annual basis.

The primary endpoints of this study were local relapse, recurrence-free survival and breast cancer-specific survival. The secondary endpoint was the cost of hospitalization. Recurrence-free survival was defined as the interval between the date of surgery and the date of breast cancer recurrence or death. The recurrence-free survival events included any recurrence of breast cancer or death, including locoregional or systemic events, excluding contralateral breast cancer. Breast cancer-specific survival was defined as the interval between the date of surgery and the date of breast cancer-related death.

Statistical Analysis

Statistical power calculation was not performed before the study. The patient characteristics were compared between the subtypes using the chi-squared test. Survival probabilities were estimated using the Kaplan–Meier method. Cox proportional hazards regression was used to assess the independent associations of several variables with recurrence-free survival. The independent sample t-test was used to assess the cost of hospitalization. Odds ratios and their 95% confidence intervals (CIs) were estimated using a Cox model with a backward stepwise method. All reported P-values were two-sided with values <.05 considered as statistically significant.
All statistical analyses were performed using SPSS 23.0 (IBM, Armonk, NY, USA).

**Results**

Among the 994 patients enrolled in our study, 367 (36.9%) received local anesthesia, and 627 (63.1%) patients underwent general anesthesia. A total of 981 (98.7%) received endocrine therapy.

Table 1 shows the clinicopathological characteristics of the two groups stratified according to the anesthetic approach. Lymph node positivity was more frequent in the general anesthesia group than in the local anesthesia group (7.8% vs 1.9%, \( P < .001 \)). Neoadjuvant treatment was used more frequently in the local anesthesia group compared to the general anesthesia group (65.4% vs 36.5%, \( P < .001 \)). There were no statistically significant differences in age, tumor size, or chemotherapy between the two groups.

The median follow-up duration was 93 months (range, 5–162 months) for all patients. The 5-year local relapse rate was 0.7% and 0.3% in the general and local anesthesia groups, respectively. The Kaplan–Meier survival curves revealed 5-year recurrence-free survival rates of 97.3% (95% CI, 95.9–98.7%) in the general anesthesia group and 96.3% (95% CI, 94.3–98.3%) in the local anesthesia group, while the respective 5-year breast cancer-specific survival rates were 99.0% (95% CI, 98.6–99.4) and 97.7% (95% CI, 96.9–98.5). There was no significant difference in the local relapse \( (P = .48) \), recurrence-free survival \( (P = .21) \) and breast cancer-specific survival \( (P = .053) \) between the two groups (Figures 1-3). Multivariable Cox regression revealed no significant association between local anesthesia and poorer recurrence-free survival (odds

---

**Table 1. Characteristics According to Anesthetic Approaches.**

| Factors                        | Local Anesthesia n=367 | General Anesthesia n=627 | \( P \) Value |
|-------------------------------|------------------------|-------------------------|--------------|
| Age (years)                   |                        |                         | .24          |
| \( \leq 40 \)                  | 61 (16.6%)             | 123 (19.6%)             |              |
| >40                           | 306 (83.4%)            | 504 (80.4%)             |              |
| Tumor size (cm)               |                        |                         | .73          |
| \( \leq 2 \)                   | 227 (61.9%)            | 402 (64.1%)             |              |
| >2                            | 124 (33.7%)            | 202 (32.2%)             |              |
| Unknown                       | 16 (4.4%)              | 23 (3.7%)               |              |
| Lymph node                    |                        |                         | <.001        |
| Negative                      | 359 (97.8%)            | 576 (91.9%)             |              |
| Positive                      | 7 (1.9%)               | 49 (7.8%)               |              |
| Unknown                       | 1 (0.3%)               | 2 (0.3%)                |              |
| Neoadjuvant treatment         |                        |                         | <.001        |
| Yes                           | 240 (65.4%)            | 229 (36.5%)             |              |
| No                            | 127 (34.6%)            | 398 (63.5%)             |              |
| Chemotherapy(neo/adjuvant)    |                        |                         | .38          |
| Yes                           | 154 (42.0%)            | 281 (44.8%)             |              |
| No                            | 213 (58.0%)            | 346 (55.2%)             |              |
| ASA physical status           |                        |                         | NA           |
| I                             | NA                     | 193 (30.8%)             |              |
| II                            | NA                     | 422 (67.3%)             |              |
| III                           | NA                     | 11 (1.8%)               |              |
| IV                            | NA                     | 1 (0.1%)                |              |
| Maintenance of general anesthesia |                  |                         | NA           |
| Intravenous anesthesia        | NA                     | 27 (4.3%)               |              |
| Inhalation anesthesia         | NA                     | 271 (43.2%)             |              |
| Both                          | NA                     | 328 (52.3%)             |              |
| Unknown                       | NA                     | 1 (0.2%)                |              |
| Operating time(min)*          | 70.08±53.19            | 81.99±27.40             | <.001        |
| Type of hospitalization       |                        |                         | <.001        |
| BCS                           | 230 (62.7%)            | 171 (27.3%)             |              |
| SLNB+BSC                      | 101 (27.5%)            | 327 (52.1%)             |              |
| BCS + chemotherapy            | 36 (9.8%)              | 129 (20.6%)             |              |
| Length of stay(day)           | 10.28 ± 5.81           | 13.33 ± 7.12            | <.001        |

ASA, American Society of Anesthesiologists; BCS, breast-conserving surgery; NA, not available; SLNB, sentinel lymph node biopsy.

*There were 14 patients with missing data of operation time in local anesthesia group.*
Table 2. Multivariable Analysis for Recurrence-Free Survival.

| Factors                  | Multivariate | Odds Ratio | 95% CI   | P Value |
|--------------------------|--------------|------------|----------|---------|
| Type of anesthesia       |              |            |          |         |
| General                  | 1            |            |          |         |
| Local                    | 1.78         | .95–3.33   | .07      |         |
| Age (years)              |              |            |          |         |
| ≤40                      | 1            |            |          |         |
| >40                      | .40          | .22–.75    | .004     |         |
| Tumor size (cm)          |              |            |          |         |
| ≤2                       | 1            |            |          |         |
| >2                       | 2.46         | 1.32–4.60  | .005     |         |
| Unknown                  | .91          | .20–4.16   | .36      |         |
| Lymph node               |              |            |          |         |
| Negative                 | 1            |            |          |         |
| Positive                 | 2.42         | .72–8.14   | .16      |         |
| Unknown                  | NA           |            |          |         |
| Neoadjuvant treatment    |              |            |          |         |
| No                       | 1            |            |          |         |
| Yes                      | .68          | .36–1.32   | .26      |         |

NA, not available.

Discussion

In this study, we found that local anesthesia or general anesthesia had no influence on local relapse or recurrence-free survival in patients who underwent breast-conserving surgery without axillary lymph node dissection. Furthermore, there was no significant association between the type of anesthesia used and prognosis after breast-conserving surgery.

Numerous comparative analyses of cancer recurrence have been conducted using data of patients who received general or general and regional anesthesia, including studies that specifically targeted patients with breast cancer. One retrospective study suggested that paravertebral anesthesia and analgesia for breast cancer surgery reduced the risk of recurrence or metastasis.15 On the other hand, two randomized trials found no apparent protective effect of regional anesthesia.16,17 Another retrospective cohort study found no significant impact of total intravenous anesthesia or inhalation anesthesia on the recurrence of breast cancer.18 Few studies have focused on local anesthesia vs general anesthesia in breast cancer. Theoretically, non-ventilated anesthesia with local anesthesia is less inflammatory and the local anesthetic acts directly on the breast cancer cells, which may reduce breast cancer recurrence. However, the present study showed that local anesthesia may not have a more positive effect on the prognosis after breast-conserving surgery compared to general anesthesia. Prospective randomized controlled trials that compare local anesthesia and general anesthesia in breast-conserving surgery are needed.

One ongoing phase III trial evaluating the effect of peri-tumoral injection of lidocaine in breast cancer (NCT01916317) may help ascertain the effects of local anesthesia alone on tumor recurrence.

This study found a strong association between age and the risk of cancer recurrence after breast-conserving surgery. Several other studies have also confirmed that the prognosis of young patients with breast cancer is significantly poorer than that of older patients.19,20 In our study, neoadjuvant treatment was more frequent in the local anesthesia group than that in the
general anesthesia group. We did not find an association between neoadjuvant treatment and recurrence-free survival. However, tumors downsized by neoadjuvant treatment may facilitate breast-conserving surgery under local anesthesia.

Our results showed a higher reduction in the total cost of hospitalization for patients who underwent breast-conserving surgery without axillary lymph node dissection using the local anesthesia method compared to general anesthesia. Similarly, several studies reported that cutaneous surgery, such as vitrectomy and thyroidectomy, could be performed under local anesthesia with lower costs.\textsuperscript{11,12} The mean operating time was shorter in the local anesthesia group than in the general anesthesia group; hence, the utilization of the operating room was reduced. In our practice, local anesthesia was administered by surgeons, and breast-conserving surgery under local anesthesia required fewer health care experts, thereby lowering the cost compared to general anesthesia.

There were several limitations to our study. First, this study was retrospective in design, and power calculation was not conducted for the estimation of the required sample size. Studies with small sample populations are usually too underpowered to show any statistical significance. Second, only patients with hormone receptor-positive and Her2-negative tumors were included because the differences in systemic treatment for triple-negative or Her2-positive patients, such as therapy with or without platinum agents and trastuzumab, may have confounded the results. Third, the surgeons decided which patients would receive local or general anesthesia, which could have introduced a degree of selection bias.

**Conclusions**

We found no significant impact of local anesthesia or general anesthesia on the local relapse and recurrence of...
breast cancer in patients who underwent breast-conserving surgery. However, local anesthesia may cost less than general anesthesia, making it a viable option for breast-conserving surgery without axillary lymph node dissection in some circumstances.

Acknowledgments
The authors would like to acknowledge Lize Wang who managed the database. We appreciate Yingjian He who worked on statistics.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by capital’s funds for health improvement and research (code: 2018-2-2152).

Ethical approval
The research protocol was examined and approved by the Ethics Committee of Beijing Cancer Hospital.

ORCID iD
Chongshan Gu https://orcid.org/0000-0002-4071-6463

References
1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;0:1-41.
2. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233-1241.
3. Christiansen P, Carstensen SL, Ejlersen B, et al. Breast conserving surgery versus mastectomy: Overall and relative survival—a population based study by the danish breast cancer cooperative group (DBCG). Acta Oncol. 2018;57:19-25.
4. Lagendijk M, van Maaren MC, Saadatmand S, et al. Breast conserving therapy and mastectomy revisited: breast cancer-specific survival and the influence of prognostic factors in 129,692 patients. Int J Cancer. 2018;142:165-175.
5. Hartmann-Johnsen OJ, Kærøsen R, Schlichting E, Nygård JF. Better survival after breast-conserving therapy compared to mastectomy when axillary node status is positive in early-stage breast cancer: A registry-based follow-up study of 6387 Norwegian women participating in screening, primarily operated between 1998 and 2009. World J Surg Oncol. 2017;15:118.
6. Gentilini OD, Cardoso M-J, Poortmans P. Less is more. Breast conservation might be even better than mastectomy in early breast cancer patients. Breast. 2017;35:32-33.
7. Lee JH, Kang SH, Kim Y, Kim HA, Kim BS. Effects of propofol-based total intravenous anesthesia on recurrence and overall survival in patients after modified radical mastectomy: A retrospective study. Korean J Anesthesiol. 2016;69:126-132.
8. Li R, Xiao C, Liu H, Huang Y, Dilger JP, Lin J. Effects of local anesthetics on breast cancer cell viability and migration. BMC Cancer. 2018;18:666.
9. Le Gac G, Angenard G, Clément B, Laviolle B, Coulouarn C, Beloeil H. Local anesthetics inhibit the growth of human hepatocellular carcinoma cells. Anesth Analg. 2017;125:1600-1609.
10. Heaney A, Buggy DJ. Can anaesthetic and analgesic techniques affect cancer recurrence or metastasis? Br J Anaesth. 2012;109:i17-i28.
11. Simanjuntak GW, Djasikusumo A, Adisasmita A, Nadjib M, Mailangkay HHB, Hussain N. Cost analysis of vitrectomy under local versus general anesthesia in a developing country. Clin Ophthalmol. 2018;12:1987-1991.
12. Spanknebel K, Chabot JA, DiGiorigi M, et al. Thyroidectomy using monitored local or conventional general anesthesia: An analysis of outpatient surgery, outcome and cost in 1,194 consecutive cases. World J Surg. 2006;30:813-824.
13. Von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147:573-577.
14. Giuliano AE, Ballman KV, McCall L, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis. JAMA. 2017;318:918-926.
15. Exadaktylos AK, Buggy DJ, Moriarty DC, Mascha E, Sessler DI. Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis? Anesthesiology. 2006;105:660-664.
16. Karmakar MK, Samy W, Lee A, et al. Survival analysis of patients with breast cancer undergoing a modified radical mastectomy with or without a thoracic paravertebral block: A 5-year follow-up of a randomized controlled trial. Anticancer Res. 2017;37:5813-5820.
17. Sessler DI, Pei L, Huang Y, et al. Recurrence of breast cancer after regional or general anaesthesia: A randomised controlled trial. Lancet. 2019;394:1807-1815.
18. Yoo S, Lee HB, Han W, et al. Total intravenous anesthesia versus inhalation anesthesia for breast cancer surgery. Anesthesiology. 2019;130:31-40.
19. Plichta JK, Thomas SM, Vernon R, et al. Breast cancer tumor histopathology, stage at presentation, and treatment in the extremes of age. Breast Cancer Res Treat. 2020;180:227-235.
20. Wang L, He Y, Li J, et al. Comparisons of breast conserving therapy versus mastectomy in young and old women with early-stage breast cancer: Long-term results using propensity score adjustment method. Breast Cancer Res Treat. 2020;183:717-728.